Surgery-first treatment improves clinical results in infective endocarditis complicated with disseminated intravascular coagulation

被引:6
|
作者
Yokoyama, Junya [1 ]
Yoshioka, Daisuke [1 ]
Toda, Koichi [1 ]
Matsuura, Ryohei [1 ]
Suzuki, Kota [1 ]
Samura, Takaaki [1 ]
Miyagawa, Shigeru [1 ]
Yoshikawa, Yasushi [1 ]
Takano, Hiroshi [2 ]
Matsumiya, Goro [3 ]
Sakaguchi, Taichi [4 ]
Fukuda, Hirotsugu [5 ]
Takahashi, Toshiki [6 ]
Izutani, Hironori [7 ]
Funatsu, Toshihiro [8 ]
Nishi, Hiroyuki [6 ]
Sawa, Yoshiki [1 ]
机构
[1] Osaka Univ Hosp, Dept Cardiovasc Surg, Yamadaoka 2-2, Suita, Osaka 5650871, Japan
[2] Dokkyo Koshigaya Med Ctr, Dept Cardiovasc Surg, Saitama, Japan
[3] Chiba Univ Hosp, Dept Cardiovasc Surg, Chiba, Japan
[4] Hyogo Coll Med, Dept Cardiovasc Surg, Nishinomiya, Hyogo, Japan
[5] Dokkyo Univ, Med Sch Hosp, Dept Cardiovasc Surg, Mibu, Tochigi, Japan
[6] Osaka Police Hosp, Dept Cardiovasc Surg, Osaka, Japan
[7] Ehime Univ Hosp, Dept Cardiovasc Surg, Matsuyama, Ehime, Japan
[8] Rinku Gen Med Ctr, Dept Cardiovasc Surg, Osaka, Japan
关键词
Infective endocarditis; Disseminated intravascular coagulation; Valve surgery; Endocarditis; ASSOCIATION; DIAGNOSIS;
D O I
10.1093/ejcts/ezz068
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES: Infective endocarditis (IE) is a critical infection with a high mortality rate, and it usually causes sepsis. Though disseminated intravascular coagulation (DIC) sometimes occurs in IE patients, no definitive treatment strategy for IE patients with DIC as a complication exists. Therefore, we evaluated the prevalence, surgical results and treatment strategy for IE complicated with DIC. METHODS: Between 2009 and 2017, a total of 585 patients undergoing valve surgery for active IE were enrolled at 14 institutions, of whom 116 (20%) had DIC as a complication. For further evaluation, we divided DIC patients into medical treatment-first (n=45, group M) and valve surgery-first (n=51, group S) groups after excluding 20 patients with intracranial haemorrhage. RESULTS: The overall survival rates at 1 and 5years were 91% and 85% in the non-DIC group and 65% and 55% in the DIC group, respectively (P<0.001). Recurrence-free survival rates at 1 and 5years were 99% and 95% in the non-DIC group and 94% and 74% in the DIC group, respectively (P<0.001). The overall survival rates at 1 and 5years were 77% and 64% in group S and 51% and 46% in group M, respectively (P=0.032). Multivariable analysis revealed that 'medical treatment first' was an exclusive independent risk factor [hazards ratio 2.26 (1.13-4.75), P=0.024] for overall mortality. CONCLUSIONS: Mortality and IE recurrence were statistically significantly higher in DIC patients. Valve surgery should not be delayed because most patients proceeding with medical treatment eventually require emergency surgery and their clinical outcomes are worse than those of patients undergoing early surgery.
引用
收藏
页码:785 / 792
页数:8
相关论文
共 49 条
  • [31] Long-Term Results of Early Surgery Versus Conventional Treatment for Infective Endocarditis Trial
    Kang, Duk-Hyun
    Lee, Sahmin
    Kim, Yong-Jin
    Kim, Dae-Hee
    Song, Jong-Min
    Choi, Kee-Joon
    Song, Jae-Kwan
    Lee, Jae-Won
    Zo, Joo-Hee
    CIRCULATION, 2015, 132
  • [32] USE OF A SYNTHETIC PROTEASE INHIBITOR FOR THE TREATMENT OF L-ASPARAGINASE-INDUCED ACUTE-PANCREATITIS COMPLICATED BY DISSEMINATED INTRAVASCULAR COAGULATION
    MURAKAWA, M
    OKAMURA, T
    SHIBUYA, T
    HARADA, M
    OTSUKA, T
    NIHO, Y
    ANNALS OF HEMATOLOGY, 1992, 64 (05) : 249 - 252
  • [33] Successful treatment with recombinant thrombomodulin for B-cell lymphoma-associated hemophagocytic syndrome complicated by disseminated intravascular coagulation
    Uni, Masahiro
    Yoshimi, Akihide
    Maki, Hiroaki
    Maeda, Daichi
    Nakazaki, Kumi
    Nakamura, Fumihiko
    Fukayama, Masashi
    Kurokawa, Mineo
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2013, 6 (06): : 1190 - 1194
  • [34] Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: A prospective clinical study
    Liu, Xiao-Li
    Wang, Xiao-Zhi
    Liu, Xiu-Xiang
    Hao, Dong
    Jaladat, Yasaman
    Lu, Feng
    Sun, Ting
    Lv, Chang-Jun
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2014, 7 (03) : 604 - 608
  • [35] Comparison of recombinant human thrombomodulin and gabexate mesylate for treatment of disseminated intravascular coagulation (DIC) with sepsis following emergent gastrointestinal surgery: a retrospective study
    Akahoshi, T.
    Sugimori, H.
    Kaku, N.
    Tokuda, K.
    Nagata, T.
    Noda, E.
    Morita, M.
    Hashizume, M.
    Maehara, Y.
    EUROPEAN JOURNAL OF TRAUMA AND EMERGENCY SURGERY, 2015, 41 (05) : 531 - 538
  • [36] Comparison of recombinant human thrombomodulin and gabexate mesylate for treatment of disseminated intravascular coagulation (DIC) with sepsis following emergent gastrointestinal surgery: a retrospective study
    T. Akahoshi
    H. Sugimori
    N. Kaku
    K. Tokuda
    T. Nagata
    E. Noda
    M. Morita
    M. Hashizume
    Y. Maehara
    European Journal of Trauma and Emergency Surgery, 2015, 41 : 531 - 538
  • [37] Recombinant Human Thrombomodulin in the Treatment of Acute Myeloid Leukemia Patients Complicated by Disseminated Intravascular Coagulation: Retrospective Analysis of the Outcomes Between the Patients with Heparin and with Recombinant Human Thrombomodulin Therapy
    Takezako, Naoki
    Sekiguchi, Naohiro
    Nagata, Akihisa
    Noto, Satoshi
    Miwa, Akiyoshi
    BLOOD, 2011, 118 (21) : 558 - 559
  • [38] Case report: PD-1 inhibitor-based treatment strategies in gastric cancer complicated by bone marrow metastasis and disseminated intravascular coagulation: A report of two cases
    Huang, Ren-Ze
    Chen, Nuo
    Hu, Yan
    Hu, Wan-Ming
    Wang, Feng-Hua
    Chen, Dong-Liang
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [39] Recombinant human thrombomodulin in the treatment of acute myeloid leukemia patients complicated by disseminated intravascular coagulation: retrospective analysis of outcomes between patients treated with heparin and recombinant human thrombomodulin therapy
    Takezako, Naoki
    Sekiguchi, Naohiro
    Nagata, Akihisa
    Homma, Chiho
    Takezako, Yayoi
    Noto, Satoshi
    Natori, Kazuhiko
    Miwa, Akiyoshi
    THROMBOSIS RESEARCH, 2015, 136 (01) : 20 - 23
  • [40] Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial
    Saito, H.
    Maruyama, I.
    Shimazaki, S.
    Yamamoto, Y.
    Aikawa, N.
    Ohno, R.
    Hirayama, A.
    Matsuda, T.
    Asakura, H.
    Nakashima, M.
    Aoki, N.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (01) : 31 - 41